Program Schedule

1052
Antibody and Cellular Immune Responses to 2011-2012 Seasonal Inactivated Influenza Vaccine in HIV-Infected and Uninfected Children and Young Adults

Session: Poster Abstract Session: Vaccines: Influenza
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • Donna Curtis - IDSA 2014 Poster.pdf (231.8 kB)
  • Background: HIV infection is associated with lower antibody responses to influenza vaccines. We compared antibody and cellular responses between HIV-infected and uninfected children and young adults to the 2011-2012 seasonal inactivated influenza vaccine (IIV3).

    Methods: 11 HIV-infected subjects and 7 controls received one dose of 2011-2012 IIV3.  Plasma and cells were frozen pre-vaccination (T1) and 2-4 weeks post-vaccination (T2).  At each timepoint, hemagglutination inhibition (HAI) was done for all 3 vaccine strains; antibody avidity (AI), B-cell memory (IgG ELISPOT), T cell response (IFNγ and IL-2 ELISPOT) for pH1N1; and B- and T-cell phenotypes (flow cytometry).  All subjects were surveyed on vaccination history during the 2010-2011 season and whether they were vaccinated prior to the 2010-2011 season.

    Results: Average CD4 count of HIV-infected was 555 (median 590), and 9/11 (82%) were on cART.  There was no significant difference between the cohorts in HAI at either timepoint, or in rates of seroprotection/seroconversion for any viruses.  Individuals in both cohorts who had not been vaccinated in prior years had a higher fold-raise (FR) in HAI to pH1N1 but not to H3 or B viruses (p=0.008). The median AI for pH1N1 was higher at baseline for HIV-infected vs. controls, 0.32 and 0.19 (p=0.003) respectively.  The AI was not different at T2 nor was the change from T1 to T2. T cell ELISPOT results were similar between cohorts. IgG ELISPOT in HIV-infected vs. controls showed no difference in numbers at T1 (4.5 vs. 4, p=NS); a trend difference at T2 (6.8 vs. 23.5, p=0.07); and significant differences in the absolute change and FR from T1 to T2 (2 vs. 18.5, p=0.04; 0.9 vs. 5.22, p=0.04).  History of prior influenza vaccine was associated with a significant difference in IgG ELISPOT FR (2.44 for vaccinated vs. 0 for unvaccinated, p=0.05) for HIV-infected, but not for controls (2.5 vaccinated vs. 15.3 unvaccinated, p=NS).  Flow cytometry revealed higher percent of tissue-like (7.8% vs. 4.1%, p=0.03) and immature (25.6% vs. 8.9%, p=0.02) B cells in HIV-infected vs. controls at baseline.

    Conclusion: Despite high cART uptake and high CD4 count, the HIV-infected cohort showed significantly lower memory B cell responses compared with controls. A history of influenza vaccine was advantageous to HIV-infected but not controls in developing a B cell IgG response.

    Donna Curtis, MD, MPH1, Alice Cho, BS2, Laura Pyle, PhD3 and Adriana Weinberg, MD1, (1)Pediatric Infectious Disease, University of Colorado Denver School of Medicine, Aurora, CO, (2)University of Colorado Denver School of Medicine, Aurora, CO, (3)Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO

    Disclosures:

    D. Curtis, Sanofi-Pasteur: Support for an Investigator-Initiated protocol, Research support

    A. Cho, None

    L. Pyle, None

    A. Weinberg, Sanofi-Pasteur: Support for an Investigator-Initiated protocol, Research support
    MedImmune: Grant Investigator, Research grant

    See more of: Vaccines: Influenza
    See more of: Poster Abstract Session
    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek